References
- Williams HC, Strachan DP. The natural history of childhood eczema: observations from the british 1958 birth cohort study. Br J Dermatol. 1998;139(5):1–2.
- Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431.
- Gargiulo L, Ibba L, Cortese A, et al. Real-Life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-Severe atopic dermatitis: a Single-Center 16-Week study. Dermatol Ther (Heidelb). 2023;13(2):651–660.
- Costanzo A, Amerio P, Asero R, Italian AD Study Group, et al. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the italian society of dermatology and venereology (SIDeMaST), the association of italian territorial and hospital allergists and immunologists (AAIITO), the italian association of hospital dermatologists (ADOI), the italian society of allergological, environmental and occupational dermatology (SIDAPA), and the italian society of allergy, asthma and clinical immunology (SIAAIC). Ital J Dermatol Venerol. 2022;157(1):1–12.
- Simpson EL, Bieber T, Guttman-Yassky E, SOLO 1 and SOLO 2 Investigators, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
- Worm M, Simpson EL, Thaçi D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:131–143.
- Patruno C, Fabbrocini G, Longo G, Dupilumab for Atopic Dermatitis of the Elderly (DADE) Study Group, et al. Effectiveness and safety of Long-Term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter Real-Life observational study. Am J Clin Dermatol. 2021;22(4):581–586.